Clinical Research Directory

Inclusion Criteria: * Age ≥ 18 years old * Signed written informed consent * French Social Security affiliation * Patients with high suspicion of or confirmed RCC requiring surgical resection * Kidney tumor diameter between 2 cm and 7 cm with clear cell imaging feature (hyper vascular lesion with contrast-enhancement similar to the renal cortex on CTA) * Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures Exclusion Criteria: * Pregnant or breastfeeding women * Patient under legal protection (guardianship) * Contraindication to the PET-CT * Contraindication to the injection of 82-Rb * Participation in another interventional study involving human participants or being in the exclusion period at the end of a previous study involving human participants, if applicable * Patient on SMA (state medical aid) * Unilateral renal agenesis * Multicystic renal dysplasia * Hereditary forms of RCC as VHL, MET, FH and FLCN * Bosniak 3 cysts * Hypovascular lesions with enhancement inferior to the renal cortex in corticomedullary-phase images on CTA * Exclusion of clear renal cell adenocarcinoma on biopsy * Kidney tumors with high suspicion of extra-renal extension (cT3b, cT3c, cN+ or M+).